Aim Sequential administration of sorafenib followed by regorafenib or lenvatinib is effective
against advanced hepatocellular carcinoma (HCC). In this study, we compared the safety …

Methods Thirty-four patients with advanced HCC were treated with sorafenib regardless of
liver function and prior anticancer therapy. Adverse events (AEs) were graded using …

Many years after therapeutic wilderness, sorafenib finally showed a clinical benefit in
patients with advanced hepatocellular carcinoma. After the primary general enthusiasm …

BACKGROUND & AIMS: Sorafenib, a multi-kinase inhibitor with anti-angiogenic activity, was
recently approved for the treatment of advanced hepatocellular carcinoma (HCC) …

4083 Background: Combining systemic and locoregional therapies represents a promising
treatment strategy for patients with advanced hepatocellular carcinoma (HCC). We …

4028 Background: HCC is a vascular tumor with poor prognosis. Although S has been
shown to improve survival, its ability to induce tumor shrinkage is very low. Given the activity …

Background Hepatocellular carcinoma is the fifth most common cancer worldwide and the
third most common cause of cancer mortality. Advanced HCC is a distinct disease entity with …

Purpose To compare the clinical outcomes of sorafenib plus either erlotinib or placebo in
patients with advanced hepatocellular carcinoma (HCC) in a multicenter, multinational …

Lenvatinib (Lenvima®) is an oral small molecule inhibitor of multiple receptor tyrosine
kinases, and is approved for the first-line treatment of patients with unresectable …

Importance of the field: With the recent advances in the knowledge of molecular biology of
hepatocellular carcinoma (HCC), there have been encouraging developments in targeted …